Biopharm ink New Year service deals in drive to enter clinic
Biopharm companies have inked a raft of contract service deals at the start of 2012 in efforts to push compounds into the clinic.
Biopharm companies have inked a raft of contract service deals at the start of 2012 in efforts to push compounds into the clinic.
Phase I data shows Alnylam a “very potent” RNAi delivery platform that can be the foundation of its future, the company’s CEO said.
The US Food and Drug Administration (FDA) will soon start asking drugmakers to play a greater role in guideline development. Before that process begins in-Pharmatechnologist.com takes a look at the documents published by the agency in 2011.
R&D software firm Accelrys says it will speed up the pharma QA/QC process and reduce the compliance risk ten-fold through its $35m takeover of VelQuest.
ACRO says latest draft rules on trials in India – which would see ethics committees take sole responsibility for determining SAE cause and compensation - are a backwards step that would make high quality research impossible.
UK-based biotech ValiRx has acquired a biomarkers business from Finnish preclinical CRO Pharmatest Services.
Gulf Pharmaceutical Industries is set to become the first insulin maker in the Middle East with its new $136m plant in Ras Al Khaimah, UAE.